期刊文献+
共找到1篇文章
< 1 >
每页显示 20 50 100
nflammasomes in cancer: a double-edgecl sword 被引量:40
1
作者 Ryan Kolb Guang-Hui Liu +2 位作者 Ann M. Janowski fayyaz s. sutterwala Weizhou Zhang 《Protein & Cell》 SCIE CAS CSCD 2014年第1期12-20,共9页
Chronic inflammatory responses have long been observed to be associated with various types of cancer and play decisive roles at different stages of cancer development. Inflammasomes, which are potent induc- ers of int... Chronic inflammatory responses have long been observed to be associated with various types of cancer and play decisive roles at different stages of cancer development. Inflammasomes, which are potent induc- ers of interleukin (IL)-I~ and IL-18 during infammation, are large protein complexes typically consisting of a Nod-like receptor (NLR), the adapter protein ASC, and Caspase-1. During malignant transformation or cancer therapy, the inflammasomes are postulated to become activated in response to danger signals arising from the tumors or from therapy-induced damage to the tumor or healthy tissue. The activation of inflammasomes plays diverse and sometimes contrasting roles in cancer promotion and therapy depending on the specific con- text. Here we summarize the role of different inflamma- some complexes in cancer progression and therapy. Inflammasome components and pathways may provide novel targets to treat certain types of cancer; however, using such agents should be cautiously evaluated due to the complex roles that inflammasomes and pro- inflammatory cytokines play in immunity. 展开更多
关键词 INFLAMMASOME CANCER INFLAMMATION
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部